Exelixis, Inc.
A biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Exelixis' stock with a target price of $34.32, indicating potential growth.
Financial Health
Exelixis, Inc. is producing strong revenue and profits, with healthy cash flow and margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EXEL
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Ongoing trials and potential label expansions could drive re‑rating, though outcomes are uncertain and can move the share price sharply.
Core drug focus
Cabozantinib is central to revenue and pipeline strategy; success in new indications could extend commercial life but competition is strong.
Partnership reach
Collaborations and licensing deals help fund development and broaden market access, though partner terms and regional reimbursement affect returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
